Summary
35 Parkinson's disease patients with motor response fluctuations (RF) participated in controlled clinical trials comparing Sinemet CR to Standard Sinemet (STD) at our institutions. 13 of 25 eligible patients continued to two years (the longest possible follow-up from the second study), and 5 of 11 have continued taking CR up to 4 years. At the end of both two and four years, patients were taking significantly fewer medication doses, with a significantly longer interdose interval, and up to two years, experienced fewer “off” periods than when on Standard Sinemet (STD) alone. Most patients required STD at at least one dose each day to hasten to onset of antiparkinson effect. Sinemet CR is a useful adjunct in the long-term management of motor response fluctuations in Parkinson's disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahlskog JE, Muenter MD, McManis PG, et al (1988) Sinemet CR-4: a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 63: 876–886
Cedarbaum JM, Breck L, Kutt H, McDowell FH (1987) Controlled-releae levodopa/carbidopa II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology 37: 1607–1612
Cedarbaum JM, Hoey M, Kutt H, McDowell FH (1988) Controlled-release levodopa/carbidopa III. Sinemet CR5 treatment of response fluctuations in Parkinson's disease. Clin Neuropharmacol 11: 168–173
Cedarbaum JM, Hoey M, McDowell FH (1989a) A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry 52: 207–212
Cedarbaum JM, Kutt H, McDowell FH (1989b) A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 39 [Suppl 2]: 38–44
Cedarbaum JM, Silvestri M (1990) Methods for assessing motor fluctuations in conducting clinical trials of antiparkinson agents. Demos Publications (in press)
Goetz CG, Tanner CM, Klawans HC, Shannon KM, Caroll VS (1987) Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR4-Sinemet). Neurology 37: 875–878
Goetz CG, Tanner CM, Gillety DW, Klawans HL (1989) Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sienemt CR versus carbidopa/levodopa. Neurology 39 [Suppl 2]: 63–66
Hutton JT, Morris JL, Roman GC, et al (1988) Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa. Arch Neurol 45: 861–864
Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S (1989) Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. Neurology 39 [Suppl 2]: 67–72
LeWitt PA, Nelson MV, Berchou RC, et al (1989) Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 39 [Suppl 2]: 45–53
Mark MH, Sage JI (1989) Long-term efficacy of controled-release carbidopa/levodopa in patients with advanced Parkinson's disease. Ann Clin Lab Sci 19: 415–421
Mouradian MM, Chase TN (1988) Hypothesis: central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 11: 378–385
Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN (1989) Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 25: 523–526
Rinne U (1987) Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease. A 5-year follow-up. Neurology 37: 826–828
Rodnitzky RL, Dickens QS, Dobson J (1989) Long-term clinical efficacy of sinemet CR in patients with Parkinson's disease. Neurology 39 [Suppl 2]: 92–95
Sage JI, Mark MH (1988) Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study. Clin Neuropharmacol 11: 174–179
Yeh KC, August TF, Bush DF, et al (1989) Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 39 [Suppl 2]: 25–38
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cedarbaum, J.M., Silvestri, M., Clark, M. et al. Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR). J Neural Transm Gen Sect 2, 205–213 (1990). https://doi.org/10.1007/BF02257651
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02257651